141 related articles for article (PubMed ID: 8922810)
21. [The significance of bacterial and host factors in corneal infections caused by Pseudomonas aeruginosa].
Steuhl KP; Döring G; Thiel HJ
Fortschr Ophthalmol; 1989; 86(4):283-6. PubMed ID: 2507425
[TBL] [Abstract][Full Text] [Related]
22. Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice.
Matsumoto T; Tateda K; Miyazaki S; Furuya N; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
J Med Microbiol; 1998 Apr; 47(4):295-301. PubMed ID: 9568994
[TBL] [Abstract][Full Text] [Related]
23. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.
Gilleland HE; Gilleland LB; Fowler MR
J Med Microbiol; 1993 Feb; 38(2):79-86. PubMed ID: 8429543
[TBL] [Abstract][Full Text] [Related]
24. Anti-lipopolysaccharide antibody levels in patients with AIDS at the onset of Pseudomonas aeruginosa bacteremia.
Kumar PN; Collins MS; Pierce PF
J Acquir Immune Defic Syndr (1988); 1994 Jun; 7(6):587-91. PubMed ID: 8176642
[TBL] [Abstract][Full Text] [Related]
25. Increased levels of IgG subclasses specific for Pseudomonas aeruginosa exoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis.
Albus A; Saalmann M; Tesch H; Pedersen SS; Döring G
APMIS; 1989 Dec; 97(12):1146-8. PubMed ID: 2482060
[TBL] [Abstract][Full Text] [Related]
26. Development of antibodies to OEP, exotoxin A and exoenzymes of Pseudomonas aeruginosa in man.
Shinozaki T; Fujii R; Sanai Y; Homma JY
Jpn J Exp Med; 1981 Jun; 51(3):165-70. PubMed ID: 6795373
[TBL] [Abstract][Full Text] [Related]
27. Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis.
Corech R; Rao A; Laxova A; Moss J; Rock MJ; Li Z; Kosorok MR; Splaingard ML; Farrell PM; Barbieri JT
J Clin Microbiol; 2005 Aug; 43(8):3956-62. PubMed ID: 16081936
[TBL] [Abstract][Full Text] [Related]
28. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model.
Manafi A; Kohanteb J; Mehrabani D; Japoni A; Amini M; Naghmachi M; Zaghi AH; Khalili N
BMC Microbiol; 2009 Feb; 9():23. PubMed ID: 19183501
[TBL] [Abstract][Full Text] [Related]
29. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.
Cryz SJ; Fürer E; Germanier R
Infect Immun; 1983 Mar; 39(3):1072-9. PubMed ID: 6404817
[TBL] [Abstract][Full Text] [Related]
30. Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteins.
Twining SS; Kirschner SE; Mahnke LA; Frank DW
Invest Ophthalmol Vis Sci; 1993 Aug; 34(9):2699-712. PubMed ID: 8344792
[TBL] [Abstract][Full Text] [Related]
31. Identification of a small epitope in domain Ib of Pseudomonas aeruginosa exotoxin A that elicits enzyme-neutralizing antibodies.
Rutault K; Coin D; Vacheron MJ; Guinand M; Wallach J; Michel G
FEMS Microbiol Immunol; 1992 Jul; 4(5):267-72. PubMed ID: 1381199
[TBL] [Abstract][Full Text] [Related]
32. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Pier GB
Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
[No Abstract] [Full Text] [Related]
33. The role of exotoxin A in pseudomonas disease and immunity.
Pollack M
Rev Infect Dis; 1983; 5 Suppl 5():S979-84. PubMed ID: 6419320
[TBL] [Abstract][Full Text] [Related]
34. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
[TBL] [Abstract][Full Text] [Related]
35. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
Johansen HK; Cryz SJ; Høiby N
APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
[TBL] [Abstract][Full Text] [Related]
36. [Production of an diagnostic erythrocyte agent from Pseudomonas aeruginosa exotoxin A].
Egizova SA; Deriabin PN; Karal'nik BV; Kanapina ASh; Moroz AF
Zh Mikrobiol Epidemiol Immunobiol; 1988 Dec; (12):38-41. PubMed ID: 3149841
[TBL] [Abstract][Full Text] [Related]
37. [Protective polysaccharide-protein artificial antigens from O-specific polysaccharides of Pseudomonas aeruginosa and its exotoxin A].
Dmitriev BA; Kul'shin VA; Antsiferova NG; Vovk VA; Moroz AF
Dokl Akad Nauk SSSR; 1988; 298(5):1277-80. PubMed ID: 2454182
[No Abstract] [Full Text] [Related]
38. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy.
Stanislavsky ES; Dmitriev BA; Lányi B; Joó I
Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389
[No Abstract] [Full Text] [Related]
39. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
40. A macromolecular structure produced by Pseudomonas aeruginosa is recognized by antibody to exotoxin A.
Klinger KW; Shuster CW
Infect Immun; 1984 Mar; 43(3):912-9. PubMed ID: 6421741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
